132 related articles for article (PubMed ID: 15229994)
1. Generic drug cost containment in Medicaid: lessons from five state MAC programs.
Abramson RG; Harrington CA; Missmar R; Li SP; Mendelson DN
Health Care Financ Rev; 2004; 25(3):25-34. PubMed ID: 15229994
[TBL] [Abstract][Full Text] [Related]
2. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.
Kelton CM; Chang LV; Kreling DH
Health Aff (Millwood); 2013 Jul; 32(7):1204-11. PubMed ID: 23836735
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals: pharmaceutical cost controls.
Seay M; Lee LL
Issue Brief Health Policy Track Serv; 2007 Jan; ():1-22. PubMed ID: 17357250
[No Abstract] [Full Text] [Related]
5. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
Seay M; Varma P
Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
[TBL] [Abstract][Full Text] [Related]
6. Medicaid cost containment and access to prescription drugs.
Cunningham PJ
Health Aff (Millwood); 2005; 24(3):780-9. PubMed ID: 15886173
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceuticals and medical devices: cost savings.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
[No Abstract] [Full Text] [Related]
8. Medicaid payment for generic drugs: achieving savings and access.
Peters CP
Issue Brief George Wash Univ Natl Health Policy Forum; 2010 Sep; (839):1-16. PubMed ID: 20928958
[TBL] [Abstract][Full Text] [Related]
9. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceuticals: Medicaid drug cost containment: year end report-2002.
Floridi T; Kammer C
Issue Brief Health Policy Track Serv; 2002 Dec; ():1-13. PubMed ID: 12856684
[No Abstract] [Full Text] [Related]
11. Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland.
Sawyer DO
Inquiry; 1983; 20(1):76-87. PubMed ID: 6219949
[TBL] [Abstract][Full Text] [Related]
12. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Bendicksen L; Rome BN; Avorn J; Kesselheim AS
Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceuticals issue brief: pharmaceuticals cost control: year end report--2004.
Seay M
Issue Brief Health Policy Track Serv; 2004 Dec; ():1-17. PubMed ID: 15724308
[No Abstract] [Full Text] [Related]
14. Evaluation of the maximum allowable cost program.
Lee AJ; Hefner D; Dobson A; Hardy R
Health Care Financ Rev; 1983 Mar; 4(3):71-82. PubMed ID: 10309857
[TBL] [Abstract][Full Text] [Related]
15. Enrollment is driving Medicaid costs--but two targets can yield savings.
Holahan J; Yemane A
Health Aff (Millwood); 2009; 28(5):1453-65. PubMed ID: 19738264
[TBL] [Abstract][Full Text] [Related]
16. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
Kesselheim AS; Fischer MA; Avorn J
Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
[TBL] [Abstract][Full Text] [Related]
17. High-cost generic drugs--implications for patients and policymakers.
Alpern JD; Stauffer WM; Kesselheim AS
N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
[TBL] [Abstract][Full Text] [Related]
18. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
[TBL] [Abstract][Full Text] [Related]
19. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
Fischer MA; Avorn J
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
[TBL] [Abstract][Full Text] [Related]
20. The state and consequences of dermatology drug prices in the United States.
Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
